An article on BioMarin Pharmaceutical Inc. in the Jan. 15, 2001, issue of BioWorld Today failed to take into account the exercise of the overallotment option from a recent public offering. Including overallotments, BioMarin grossed $96.6 million in the offering, netting about $90.8 million.

Editor’s note: The correction has been made in BioWorld Online.